[go: up one dir, main page]

UY25071A1 - SOLTRILIZED COMPOSITIONS OF SERTRALINA - Google Patents

SOLTRILIZED COMPOSITIONS OF SERTRALINA

Info

Publication number
UY25071A1
UY25071A1 UY25071A UY25071A UY25071A1 UY 25071 A1 UY25071 A1 UY 25071A1 UY 25071 A UY25071 A UY 25071A UY 25071 A UY25071 A UY 25071A UY 25071 A1 UY25071 A1 UY 25071A1
Authority
UY
Uruguay
Prior art keywords
compositions
soltrilized
sertralina
sertraline
solubilizing agent
Prior art date
Application number
UY25071A
Other languages
Spanish (es)
Inventor
Dwayne Thomas Friesen
Scott Max Herbig
Ravi Mysore Shanker
James Blair West
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21971159&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY25071(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of UY25071A1 publication Critical patent/UY25071A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Composiciones que contienen sertralina y un agente solubilizante que aumente la solubilidad de la sertralina en medios acuosos que contienen ion cloruro, como los fluidos del tracto gi. Dicho agente solubilizante puede pertenecer a varios grupos: ácidos orgánicos y sus sales; mono, di o triglicéridos o sus derivados; esteres de peg; esteres de sorbitano; esteres de alcoholes polihidroxilados,...Compositions containing sertraline and a solubilizing agent that increases the solubility of sertraline in aqueous media containing chloride ion, such as fluids from the gi tract. Said solubilizing agent can belong to several groups: organic acids and their salts; mono, di or triglycerides or their derivatives; peg mats; sorbitan esters; polyhydroxy alcohol esters, ...

UY25071A 1997-07-01 1998-06-29 SOLTRILIZED COMPOSITIONS OF SERTRALINA UY25071A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5141397P 1997-07-01 1997-07-01

Publications (1)

Publication Number Publication Date
UY25071A1 true UY25071A1 (en) 2000-12-29

Family

ID=21971159

Family Applications (1)

Application Number Title Priority Date Filing Date
UY25071A UY25071A1 (en) 1997-07-01 1998-06-29 SOLTRILIZED COMPOSITIONS OF SERTRALINA

Country Status (34)

Country Link
EP (1) EP0999829A1 (en)
JP (1) JP2000514100A (en)
KR (1) KR100366373B1 (en)
CN (1) CN1261794A (en)
AP (1) AP1192A (en)
AR (3) AR015917A1 (en)
AU (1) AU742535B2 (en)
BG (1) BG103918A (en)
BR (1) BR9810739A (en)
CA (1) CA2290974C (en)
CO (1) CO4940495A1 (en)
DZ (1) DZ2548A1 (en)
EA (1) EA002481B1 (en)
HN (1) HN1998000102A (en)
HR (1) HRP980377A2 (en)
HU (1) HUP0002236A3 (en)
ID (1) ID23429A (en)
IL (1) IL133076A (en)
IS (1) IS5260A (en)
MA (1) MA24587A1 (en)
NO (1) NO996520L (en)
OA (1) OA11243A (en)
PA (1) PA8454301A1 (en)
PE (1) PE97199A1 (en)
PL (1) PL337804A1 (en)
SK (1) SK181099A3 (en)
TN (1) TNSN98124A1 (en)
TR (1) TR199903297T2 (en)
TW (1) TW550087B (en)
UA (1) UA67741C2 (en)
UY (1) UY25071A1 (en)
WO (1) WO1999001120A1 (en)
YU (1) YU68299A (en)
ZA (1) ZA985708B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200201617T2 (en) 1999-12-23 2002-10-21 Pfizer Products Inc. Pharmaceutical compositions that provide enhanced drug concentrations
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
CA2420535A1 (en) 2000-08-30 2002-03-07 Mary Tanya Am Ende Sustained release formulations for growth hormone secretagogues
US20040191207A1 (en) * 2003-03-31 2004-09-30 Lipari John M. Alpha-hydroxy acid ester drug delivery compositions and methods of use
US20100105638A1 (en) * 2007-03-12 2010-04-29 Kerstin Den-Braven Cosmetic compositions
AU2010285740C1 (en) 2009-08-19 2016-03-17 Eisai R&D Management Co., Ltd. Quinoline derivative-containing pharmaceutical composition
WO2011081118A1 (en) * 2009-12-29 2011-07-07 興和株式会社 Pharmaceutical composition for oral administration
WO2011081117A1 (en) * 2009-12-29 2011-07-07 興和株式会社 Solid pharmaceutical composition for oral administration
CN109908354A (en) * 2017-12-12 2019-06-21 万特制药(海南)有限公司 Sertraline hydrochloride takes orally concentrate and its preparation process
CN114894736B (en) * 2022-05-20 2025-03-21 中化地质矿山总局地质研究院 A method for determining nitrate in chloride-type brine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4803076A (en) * 1986-09-04 1989-02-07 Pfizer Inc. Controlled release device for an active substance
EP0415612B1 (en) * 1989-08-30 1993-11-10 Pfizer Inc. Use of sertraline for the treatment of chemical dependencies
ZA97976B (en) * 1996-04-05 1997-08-18 Alza Corp Uniform drug delivery theraphy.

Also Published As

Publication number Publication date
NO996520L (en) 2000-02-29
ZA985708B (en) 2000-01-10
HRP980377A2 (en) 1999-04-30
CO4940495A1 (en) 2000-07-24
AU7544898A (en) 1999-01-25
IS5260A (en) 1999-11-19
JP2000514100A (en) 2000-10-24
HN1998000102A (en) 1999-01-08
KR100366373B1 (en) 2003-01-14
UA67741C2 (en) 2004-07-15
TR199903297T2 (en) 2000-07-21
PA8454301A1 (en) 2000-09-29
TW550087B (en) 2003-09-01
IL133076A0 (en) 2001-03-19
PE97199A1 (en) 1999-10-05
CA2290974A1 (en) 1999-01-14
AR015917A1 (en) 2001-05-30
HUP0002236A2 (en) 2003-08-28
AU742535B2 (en) 2002-01-03
BR9810739A (en) 2000-09-12
EA199900962A1 (en) 2000-08-28
AP9801280A0 (en) 1998-06-30
DZ2548A1 (en) 2003-02-08
AR040280A2 (en) 2005-03-23
PL337804A1 (en) 2000-09-11
SK181099A3 (en) 2000-07-11
EP0999829A1 (en) 2000-05-17
TNSN98124A1 (en) 2005-03-15
CN1261794A (en) 2000-08-02
EA002481B1 (en) 2002-06-27
KR20010013365A (en) 2001-02-26
NO996520D0 (en) 1999-12-28
OA11243A (en) 2003-07-24
MA24587A1 (en) 1998-12-31
AR040279A2 (en) 2005-03-23
AP1192A (en) 2003-07-23
ID23429A (en) 2000-04-20
CA2290974C (en) 2004-04-27
WO1999001120A1 (en) 1999-01-14
IL133076A (en) 2003-12-10
HUP0002236A3 (en) 2003-12-29
BG103918A (en) 2000-07-31
YU68299A (en) 2002-06-19

Similar Documents

Publication Publication Date Title
AR046970A1 (en) FLORPHENICOL PHOSPHATE ESTERS
ES2609105T3 (en) Covalent linking method of hyaluronic acid and chitosan
ES2092958B1 (en) PROCEDURE FOR THE SYNTHESIS OF CATIONIC SURFACES DERIVED FROM THE CONDENSATION OF FATTY ACIDS WITH ESTERIFIED BASIC CHARACTER AMINO ACIDS AND THEIR APPLICATION AS ANTIMICROBIAL AGENTS.
UY25071A1 (en) SOLTRILIZED COMPOSITIONS OF SERTRALINA
ES2530753T3 (en) Therapeutic compositions comprising ketone bodies and precursors thereof
DK1034251T3 (en) Simulated biological dissolution and absorption system
ID21473A (en) PHARMACEUTICAL PRICES CONTAINING EICOSAPENTANOIC ACID AND STEARIDONIC ACID
GT199900150A (en) 1,2,3,4-TETRAHYDROQUINOLINS 2-SUBSTITUTED 4-CARBOXYAMIN SUBSTITUTED.
ES2107851T3 (en) FINISHED, STABLE, POLYPHASIC, AQUEOUS FORMULATION FOR ACTIVE PLANT PROTECTIVE PRODUCTS AND PROCEDURE FOR THEIR OBTAINING.
ES2065178T3 (en) OSMOTIC DEVICE FOR DELAYED DELIVERY OF AN AGENT.
NO20101157L (en) FAD4, FAD5, FAD5-2 and FAD6, new fatty acid desaturase family members and uses thereof
DE60233420D1 (en) Fumagillol derivatives and process for their preparation
ES2122268T3 (en) AGRICULTURAL FORMULATIONS CONTAINING FLUROXIPIR LIQUID ESTERS.
ES2526912T3 (en) Pharmaceutical composition containing botulinum neurotoxin A2
ES2125535T5 (en) BLENDS, CONTAINING EMULSIONABLE ISOCIANATES IN WATER.
PT1124415E (en) AGENTS REPELLENT AND DEACTIVATION OF PLANT AGENTS
IT1317033B1 (en) METHOD OF EXTRACTION OF PHARMACEUTICAL ACTIVITY PRODUCTS FROM PLANTS SPERMATOPHYTES, PRODUCTS SO OBTAINED AND THEIR USE IN MEDICINE, IN
PE20030298A1 (en) WATER FILTERS AND PROCESSES FOR THE USE OF THEM
BRPI0407652A (en) method for enhancing the effectiveness of an active agent, composition and method for producing the composition
BR9609610A (en) esters of iodinated fatty acids, iodinated fatty acids and their derivatives, obtained by iodohydration, involving the introduction of alkylated alkylated derivatives with alkaline iodides and their pharmacological activities
MX169931B (en) PROCEDURE TO DETERMINE THE CATIVITY OF SERINPROTEASAS INHIBITORS OF SERINPROTEASAS
ES2195040T3 (en) CONJUGADO THAT INCLUDES AN ACTIVE PRINCIPLE, A POLYPEPTIDE AND VARIOUS POLIETERES AND ITS USE AS A MEDICINAL PRODUCT.
ATE334214T1 (en) FATTY ACID DESATURASE GENE FROM PLANTS
PE2596A1 (en) TRANSDERMIC APPLICATION OF ANTIEPILEPTIC DRUGS
ES2143833T3 (en) ACIDS AND ESTERS OF DIOSMETINE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.

Legal Events

Date Code Title Description
VENC Patent expired

Effective date: 20180629